

Barton F Haynes

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3758753/barton-f-haynes-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

260
papers

21,814
citations

71
h-index

143
g-index

277
ext. papers

26,348
ext. citations

14.8
avg, IF

6.74
L-index

#	Paper	IF	Citations
260	Mouse and human antibodies bind HLA-E-leader peptide complexes and enhance NK cell cytotoxicity.. <i>Communications Biology</i> , 2022 , 5, 271	6.7	1
259	mRNA-encoded HIV-1 Env trimer ferritin nanoparticles induce monoclonal antibodies that neutralize heterologous HIV-1 isolates in mice.. <i>Cell Reports</i> , 2022 , 38, 110514	10.6	2
258	Structural basis of glycan276-dependent recognition by HIV-1 broadly neutralizing antibodies. <i>Cell Reports</i> , 2021 , 37, 109922	10.6	1
257	A broadly cross-reactive antibody neutralizes and protects against sarbecovirus challenge in mice. <i>Science Translational Medicine</i> , 2021 , eabj7125	17.5	24
256	Selection of HIV Envelope strains for standardized assessments of vaccine-elicited antibody-dependent cellular cytotoxicity (ADCC)-mediating antibodies. <i>Journal of Virology</i> , 2021 , JVI0164321	6.6	3
255	Strategies for eliciting multiple lineages of broadly neutralizing antibodies to HIV by vaccination. <i>Current Opinion in Virology</i> , 2021 , 51, 172-178	7.5	2
254	Strategies for induction of HIV-1 envelope-reactive broadly neutralizing antibodies. <i>Journal of the International AIDS Society</i> , 2021 , 24 Suppl 7, e25831	5.4	5
253	Development of mRNA Manufacturing for Vaccines and Therapeutics: mRNA Platform Requirements and Development of a Scalable Production Process to Support Early Phase Clinical Trials. <i>Translational Research</i> , 2021 ,	11	3
252	Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice 2021 ,		11
251	Protein/AS01 vaccination elicits stronger, more Th2-skewed antigen-specific human T follicular helper cell responses than heterologous viral vectors. <i>Cell Reports Medicine</i> , 2021 , 2, 100207	18	6
250	Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates. <i>Npj Vaccines</i> , 2021 , 6, 50	9.5	19
249	SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines. <i>Cell Host and Microbe</i> , 2021 , 29, 529-539.e3	23.4	225
248	Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses. <i>Nature</i> , 2021 , 594, 553-559	50.4	85
247	Mapping the SARS-CoV-2 spike glycoprotein-derived peptidome presented by HLA class II on dendritic cells. <i>Cell Reports</i> , 2021 , 35, 109179	10.6	20
246	Fab-dimerized glycan-reactive antibodies are a structural category of natural antibodies. <i>Cell</i> , 2021 , 184, 2955-2972.e25	56.2	22
245	New SHIVs and Improved Design Strategy for Modeling HIV-1 Transmission, Immunopathogenesis, Prevention and Cure. <i>Journal of Virology</i> , 2021 ,	6.6	7
244	Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions. <i>Cell Reports Medicine</i> , 2021 , 2, 100313	18	24

243	Structural and genetic convergence of HIV-1 neutralizing antibodies in vaccinated non-human primates. <i>PLoS Pathogens</i> , 2021 , 17, e1009624	7.6	
242	SARS-CoV-2 and HIV-1 - a tale of two vaccines. <i>Nature Reviews Immunology</i> , 2021 , 21, 543-544	36.5	4
241	D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization. <i>Cell Host and Microbe</i> , 2021 , 29, 23-31.e4	23.4	198
240	Recapitulation of HIV-1 Env-antibody coevolution in macaques leading to neutralization breadth. <i>Science</i> , 2021 , 371,	33.3	22
239	D614G Mutation Alters SARS-CoV-2 Spike Conformation and Enhances Protease Cleavage at the S1/S2 Junction. <i>Cell Reports</i> , 2021 , 34, 108630	10.6	123
238	SARS-CoV-2 vaccination induces neutralizing antibodies against pandemic and pre-emergent SARS-related coronaviruses in monkeys 2021 ,		4
237	HIV mRNA Vaccines-Progress and Future Paths. <i>Vaccines</i> , 2021 , 9,	5.3	18
236	Vaccine Innovations - Past and Future. <i>New England Journal of Medicine</i> , 2021 , 384, 393-396	59.2	8
235	HIV envelope antigen valency on peptide nanofibers modulates antibody magnitude and binding breadth. <i>Scientific Reports</i> , 2021 , 11, 14494	4.9	2
234	Rapid selection of HIV envelopes that bind to neutralizing antibody B cell lineage members with functional improbable mutations. <i>Cell Reports</i> , 2021 , 36, 109561	10.6	2
233	In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies. <i>Cell</i> , 2021 , 184, 4203-4219.e32	56.2	89
232	SARS-CoV-2 Neutralizing Antibodies for COVID-19 Prevention and Treatment. <i>Annual Review of Medicine</i> , 2021 ,	17.4	25
231	Ability of nucleoside-modified mRNA to encode HIV-1 envelope trimer nanoparticles 2021 ,		1
230	Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice. <i>Science</i> , 2021 , 373, 991-998	35.3	48
229	The transcription factor CREB1 is a mechanistic driver of immunogenicity and reduced HIV-1 acquisition following ALVAC vaccination. <i>Nature Immunology</i> , 2021 , 22, 1294-1305	19.1	5
228	SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral Spike vaccines 2021 ,		29
227	Cold sensitivity of the SARS-CoV-2 spike ectodomain. <i>Nature Structural and Molecular Biology</i> , 2021 , 28, 128-131	17.6	34
226	How Does HIV Env Structure Informs Vaccine Design?. <i>Microscopy and Microanalysis</i> , 2020 , 26, 574-575	0.5	

225	Therapeutic vaccination with IDLV-SIV-Gag results in durable viremia control in chronically SHIV-infected macaques. <i>Npj Vaccines</i> , 2020 , 5, 36	9.5	5
224	Co-immunization of DNA and Protein in the Same Anatomical Sites Induces Superior Protective Immune Responses against SHIV Challenge. <i>Cell Reports</i> , 2020 , 31, 107624	10.6	19
223	Maternal Broadly Neutralizing Antibodies Can Select for Neutralization-Resistant, Infant-Transmitted/Founder HIV Variants. <i>MBio</i> , 2020 , 11,	7.8	15
222	Pandemic Preparedness: Developing Vaccines and Therapeutic Antibodies For COVID-19. <i>Cell</i> , 2020 , 181, 1458-1463	56.2	70
221	Conditional antibody expression to avoid central B cell deletion in humanized HIV-1 vaccine mouse models. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020 , 117, 7929-7940	11.5	2
220	Subordinate Effect of -21M HLA-B Dimorphism on NK Cell Repertoire Diversity and Function in HIV-1 Infected Individuals of African Origin. <i>Frontiers in Immunology</i> , 2020 , 11, 156	8.4	5
219	Induction of Neutralizing Responses against Autologous Virus in Maternal HIV Vaccine Trials. <i>MSphere</i> , 2020 , 5,	5	1
218	Immune checkpoint modulation enhances HIV-1 antibody induction. <i>Nature Communications</i> , 2020 , 11, 948	17.4	9
217	Neonatal Rhesus Macaques Have Distinct Immune Cell Transcriptional Profiles following HIV Envelope Immunization. <i>Cell Reports</i> , 2020 , 30, 1553-1569.e6	10.6	10
216	Disruption of the HIV-1 Envelope allosteric network blocks CD4-induced rearrangements. <i>Nature Communications</i> , 2020 , 11, 520	17.4	24
215	Aberrant B cell repertoire selection associated with HIV neutralizing antibody breadth. <i>Nature Immunology</i> , 2020 , 21, 199-209	19.1	22
214	HIV vaccine delayed boosting increases Env variable region 2-specific antibody effector functions. <i>JCI Insight</i> , 2020 , 5,	9.9	11
213	Improved killing of HIV-infected cells using three neutralizing and non-neutralizing antibodies. <i>Journal of Clinical Investigation</i> , 2020 , 130, 5157-5170	15.9	12
212	-Deficient Mice Exhibit Cytokine-Related Transcriptomic Signatures. <i>ImmunoHorizons</i> , 2020 , 4, 713-728	2.7	
211	Cold sensitivity of the SARS-CoV-2 spike ectodomain 2020 ,		6
210	Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates 2020 ,		20
209	Prospects for a safe COVID-19 vaccine. <i>Science Translational Medicine</i> , 2020 , 12,	17.5	99
208	Immunogenicity, safety, and efficacy of sequential immunizations with an SIV-based IDLV expressing CH505 Envs. <i>Npj Vaccines</i> , 2020 , 5, 107	9.5	5

207	Recognition Patterns of the C1/C2 Epitopes Involved in Fc-Mediated Response in HIV-1 Natural Infection and the RV114 Vaccine Trial. <i>MBio</i> , 2020 , 11,	7.8	2
206	A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice. <i>Immunity</i> , 2020 , 53, 724-732.e7	32.3	132
205	Antigenicity and Immunogenicity of HIV-1 Envelope Trimers Complexed to a Small-Molecule Viral Entry Inhibitor. <i>Journal of Virology</i> , 2020 , 94,	6.6	2
204	Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies. <i>PLoS Pathogens</i> , 2019 , 15, e1008026	7.6	33
203	Star nanoparticles delivering HIV-1 peptide minimal immunogens elicit near-native envelope antibody responses in nonhuman primates. <i>PLoS Biology</i> , 2019 , 17, e3000328	9.7	24
202	The Chimpanzee SIV Envelope Trimer: Structure and Deployment as an HIV Vaccine Template. <i>Cell Reports</i> , 2019 , 27, 2426-2441.e6	10.6	20
201	Consistent elicitation of cross-clade HIV-neutralizing responses achieved in guinea pigs after fusion peptide priming by repetitive envelope trimer boosting. <i>PLoS ONE</i> , 2019 , 14, e0215163	3.7	25
200	Longitudinal Analysis Reveals Early Development of Three MPER-Directed Neutralizing Antibody Lineages from an HIV-1-Infected Individual. <i>Immunity</i> , 2019 , 50, 677-691.e13	32.3	38
199	Characterization of HIV-1 Nucleoside-Modified mRNA Vaccines in Rabbits and Rhesus Macaques. <i>Molecular Therapy - Nucleic Acids</i> , 2019 , 15, 36-47	10.7	53
198	Selection of immunoglobulin elbow region mutations impacts interdomain conformational flexibility in HIV-1 broadly neutralizing antibodies. <i>Nature Communications</i> , 2019 , 10, 654	17.4	18
197	HLA class II-Restricted CD8+ T cells in HIV-1 Virus Controllers. <i>Scientific Reports</i> , 2019 , 9, 10165	4.9	4
196	Parallel Induction of CH505 B Cell Ontogeny-Guided Neutralizing Antibodies and tHIVconsvX Conserved Mosaic-Specific T Cells against HIV-1. <i>Molecular Therapy - Methods and Clinical Development</i> , 2019 , 14, 148-160	6.4	0
195	Difficult-to-neutralize global HIV-1 isolates are neutralized by antibodies targeting open envelope conformations. <i>Nature Communications</i> , 2019 , 10, 2898	17.4	24
194	Multiple roles for HIV broadly neutralizing antibodies. <i>Science Translational Medicine</i> , 2019 , 11,	17.5	77
193	Self-tolerance curtails the B cell repertoire to microbial epitopes. <i>JCI Insight</i> , 2019 , 4,	9.9	14
192	Vaccine induction of antibodies and tissue-resident CD8+ T cells enhances protection against mucosal SHIV-infection in young macaques. <i>JCI Insight</i> , 2019 , 4,	9.9	31
191	Contribution of proteasome-catalyzed peptide -splicing to viral targeting by CD8 T cells in HIV-1 infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019 , 116, 24748-24759	11.5	27
190	Cross-Reactivity to Kynureninase Tolerizes B Cells That Express the HIV-1 Broadly Neutralizing Antibody 2F5. <i>Journal of Immunology</i> , 2019 , 203, 3268-3281	5.3	5

189	Cooperation between somatic mutation and germline-encoded residues enables antibody recognition of HIV-1 envelope glycans. <i>PLoS Pathogens</i> , 2019 , 15, e1008165	7.6	4
188	Targeted selection of HIV-specific antibody mutations by engineering B cell maturation. <i>Science</i> , 2019 , 366,	33.3	60
187	HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design. <i>Cell Host and Microbe</i> , 2019 , 25, 59-72.e8	23.4	56
186	HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees. <i>Journal of Virology</i> , 2018 , 92,	6.6	33
185	Immunogenicity of NYVAC Prime-Protein Boost Human Immunodeficiency Virus Type 1 Envelope Vaccination and Simian-Human Immunodeficiency Virus Challenge of Nonhuman Primates. <i>Journal of Virology</i> , 2018 , 92,	6.6	8
184	HIV-1-Specific IgA Monoclonal Antibodies from an HIV-1 Vaccinee Mediate Galactosylceramide Blocking and Phagocytosis. <i>Journal of Virology</i> , 2018 , 92,	6.6	25
183	HIV envelope V3 region mimic embodies key features of a broadly neutralizing antibody lineage epitope. <i>Nature Communications</i> , 2018 , 9, 1111	17.4	17
182	What Are the Primary Limitations in B-Cell Affinity Maturation, and How Much Affinity Maturation Can We Drive with Vaccination? Breaking through Immunity's Glass Ceiling. <i>Cold Spring Harbor Perspectives in Biology</i> , 2018 , 10,	10.2	8
181	Glycoengineering HIV-1 Env creates Supercharged and Hybrid Glycans to increase neutralizing antibody potency, breadth and saturation. <i>PLoS Pathogens</i> , 2018 , 14, e1007024	7.6	12
180	Correlation Between Anti-gp41 Antibodies and Virus Infectivity Decay During Primary HIV-1 Infection. <i>Frontiers in Microbiology</i> , 2018 , 9, 1326	5.7	10
179	Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses. <i>Journal of Experimental Medicine</i> , 2018 , 215, 1571-1588	16.6	212
178	Functional Relevance of Improbable Antibody Mutations for HIV Broadly Neutralizing Antibody Development. <i>Cell Host and Microbe</i> , 2018 , 23, 759-765.e6	23.4	55
177	A CD4-mimetic compound enhances vaccine efficacy against stringent immunodeficiency virus challenge. <i>Nature Communications</i> , 2018 , 9, 2363	17.4	24
176	Combination Adenovirus and Protein Vaccines Prevent Infection or Reduce Viral Burden after Heterologous Clade C Simian-Human Immunodeficiency Virus Mucosal Challenge. <i>Journal of Virology</i> , 2018 , 92,	6.6	19
175	IDLV-HIV-1 Env vaccination in non-human primates induces affinity maturation of antigen-specific memory B cells. <i>Communications Biology</i> , 2018 , 1, 134	6.7	15
174	HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies. <i>PLoS Pathogens</i> , 2018 , 14, e1007431	7.6	20
173	Inference of the HIV-1 VRC01 Antibody Lineage Unmutated Common Ancestor Reveals Alternative Pathways to Overcome a Key Glycan Barrier. <i>Immunity</i> , 2018 , 49, 1162-1174.e8	32.3	32
172	RAB11FIP5 Expression and Altered Natural Killer Cell Function Are Associated with Induction of HIV Broadly Neutralizing Antibody Responses. <i>Cell</i> , 2018 , 175, 387-399.e17	56.2	42

171	Single-Cell Analysis of Quiescent HIV Infection Reveals Host Transcriptional Profiles that Regulate Proviral Latency. <i>Cell Reports</i> , 2018 , 25, 107-117.e3	10.6	45
170	Completeness of HIV-1 Envelope Glycan Shield at Transmission Determines Neutralization Breadth. <i>Cell Reports</i> , 2018 , 25, 893-908.e7	10.6	65
169	Route of immunization defines multiple mechanisms of vaccine-mediated protection against SIV. <i>Nature Medicine</i> , 2018 , 24, 1590-1598	50.5	73
168	Tracking HIV-1 recombination to resolve its contribution to HIV-1 evolution in natural infection. <i>Nature Communications</i> , 2018 , 9, 1928	17.4	46
167	Systemic administration of an HIV-1 broadly neutralizing dimeric IgA yields mucosal secretory IgA and virus neutralization. <i>Mucosal Immunology</i> , 2017 , 10, 228-237	9.2	21
166	Resistance to type 1 interferons is a major determinant of HIV-1 transmission fitness. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017 , 114, E590-E599	11.5	92
165	The quest for an antibody-based HIV vaccine. <i>Immunological Reviews</i> , 2017 , 275, 5-10	11.3	71
164	Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. <i>Nature</i> , 2017 , 543, 248-251	50.4	502
163	Antibody-virus co-evolution in HIV infection: paths for HIV vaccine development. <i>Immunological Reviews</i> , 2017 , 275, 145-160	11.3	102
162	Host controls of HIV broadly neutralizing antibody development. <i>Immunological Reviews</i> , 2017 , 275, 79-88	11.3	53
161	Immunodominance of Antibody Recognition of the HIV Envelope V2 Region in Ig-Humanized Mice. <i>Journal of Immunology</i> , 2017 , 198, 1047-1055	5.3	5
160	Influence of the Envelope gp120 Phe 43 Cavity on HIV-1 Sensitivity to Antibody-Dependent Cell-Mediated Cytotoxicity Responses. <i>Journal of Virology</i> , 2017 , 91,	6.6	30
159	Glycosylation Benchmark Profile for HIV-1 Envelope Glycoprotein Production Based on Eleven Env Trimers. <i>Journal of Virology</i> , 2017 , 91,	6.6	65
158	BCR and Endosomal TLR Signals Synergize to Increase AID Expression and Establish Central B Cell Tolerance. <i>Cell Reports</i> , 2017 , 18, 1627-1635	10.6	39
157	Potent and broad HIV-neutralizing antibodies in memory B cells and plasma. <i>Science Immunology</i> , 2017 , 2,	28	86
156	Vaccine Elicitation of High Mannose-Dependent Neutralizing Antibodies against the V3-Glycan Broadly Neutralizing Epitope in Nonhuman Primates. <i>Cell Reports</i> , 2017 , 18, 2175-2188	10.6	50
155	Quantification of the Impact of the HIV-1-Glycan Shield on Antibody Elicitation. <i>Cell Reports</i> , 2017 , 19, 719-732	10.6	123
154	Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge. <i>Nature Communications</i> , 2017 , 8, 15711	17.4	94

153	Staged induction of HIV-1 glycan-dependent broadly neutralizing antibodies. <i>Science Translational Medicine</i> , 2017 , 9,	17.5	127
152	Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide. <i>Science Translational Medicine</i> , 2017 , 9,	17.5	59
151	Developing an HIV vaccine. <i>Science</i> , 2017 , 355, 1129-1130	33.3	68
150	HIV-1 Consensus Envelope-Induced Broadly Binding Antibodies. <i>AIDS Research and Human Retroviruses</i> , 2017 , 33, 859-868	1.6	9
149	HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine. <i>Journal of Virology</i> , 2017 , 91,	6.6	19
148	Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative women. <i>PLoS ONE</i> , 2017 , 12, e0176428	3.7	11
147	Initiation of HIV neutralizing B cell lineages with sequential envelope immunizations. <i>Nature Communications</i> , 2017 , 8, 1732	17.4	52
146	Development of a recombinant yellow fever vector expressing a HIV clade C founder envelope gp120. <i>Journal of Virological Methods</i> , 2017 , 249, 85-93	2.6	2
145	Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate Antibody-Dependent Cellular Cytotoxicity, and Protect Mice from Ocular Challenge with HSV-1. <i>Journal of Virology</i> , 2017 , 91,	6.6	16
144	Sequence intrinsic somatic mutation mechanisms contribute to affinity maturation of VRC01-class HIV-1 broadly neutralizing antibodies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017 , 114, 8614-8619	11.5	25
143	HIV DNA-Adenovirus Multiclade Envelope Vaccine Induces gp41 Antibody Immunodominance in Rhesus Macaques. <i>Journal of Virology</i> , 2017 , 91,	6.6	12
142	Short Communication: Small-Molecule CD4 Mimetics Sensitize HIV-1-Infected Cells to Antibody-Dependent Cellular Cytotoxicity by Antibodies Elicited by Multiple Envelope Glycoprotein Immunogens in Nonhuman Primates. <i>AIDS Research and Human Retroviruses</i> , 2017 , 33, 428-431	1.6	14
141	Broadly Neutralizing Antibodies Display Potential for Prevention of HIV-1 Infection of Mucosal Tissue Superior to That of Nonneutralizing Antibodies. <i>Journal of Virology</i> , 2017 , 91,	6.6	21
140	Vaccine Induction of Heterologous Tier 2 HIV-1 Neutralizing Antibodies in Animal Models. <i>Cell Reports</i> , 2017 , 21, 3681-3690	10.6	67
139	Structure and Diversity of the Rhesus Macaque Immunoglobulin Loci through Multiple Genome Assemblies. <i>Frontiers in Immunology</i> , 2017 , 8, 1407	8.4	42
138	Computational analysis of antibody dynamics identifies recent HIV-1 infection. <i>JCI Insight</i> , 2017 , 2,	9.9	8
137	Novel Monoclonal Antibodies for Studies of Human and Rhesus Macaque Secretory Component and Human J-Chain. <i>Monoclonal Antibodies in Immunodiagnosis and Immunotherapy</i> , 2016 , 35, 217-26	1.9	7
136	HIV-1 Envelope Mimicry of Host Enzyme Kynureninase Does Not Disrupt Tryptophan Metabolism. <i>Journal of Immunology</i> , 2016 , 197, 4663-4673	5.3	5

135	Latency reversal and viral clearance to cure HIV-1. <i>Science</i> , 2016 , 353, aaf6517	33.3	159
134	Initiation of immune tolerance-controlled HIV gp41 neutralizing B cell lineages. <i>Science Translational Medicine</i> , 2016 , 8, 336ra62	17.5	65
133	Immune perturbations in HIV-1-infected individuals who make broadly neutralizing antibodies. <i>Science Immunology</i> , 2016 , 1, aag0851	28	82
132	Influenza immunization elicits antibodies specific for an egg-adapted vaccine strain. <i>Nature Medicine</i> , 2016 , 22, 1465-1469	50.5	73
131	Amino Acid Changes in the HIV-1 gp41 Membrane Proximal Region Control Virus Neutralization Sensitivity. <i>EBioMedicine</i> , 2016 , 12, 196-207	8.8	28
130	Envelope residue 375 substitutions in simian-human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, E3413-22	11.5	132
129	Antibodies Elicited by Multiple Envelope Glycoprotein Immunogens in Primates Neutralize Primary Human Immunodeficiency Viruses (HIV-1) Sensitized by CD4-Mimetic Compounds. <i>Journal of Virology</i> , 2016 , 90, 5031-5046	6.6	27
128	HIV-Host Interactions: Implications for Vaccine Design. <i>Cell Host and Microbe</i> , 2016 , 19, 292-303	23.4	108
127	Maturation Pathway from Germline to Broad HIV-1 Neutralizer of a CD4-Mimic Antibody. <i>Cell</i> , 2016 , 165, 449-63	56.2	209
126	Combined HIV-1 Envelope Systemic and Mucosal Immunization of Lactating Rhesus Monkeys Induces a Robust Immunoglobulin A Isotype B Cell Response in Breast Milk. <i>Journal of Virology</i> , 2016 , 90, 4951-4965	6.6	21
125	Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design. <i>Nature Structural and Molecular Biology</i> , 2016 , 23, 81-90	17.6	126
124	Structural Constraints of Vaccine-Induced Tier-2 Autologous HIV Neutralizing Antibodies Targeting the Receptor-Binding Site. <i>Cell Reports</i> , 2016 , 14, 43-54	10.6	45
123	New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency. <i>Journal of Virology</i> , 2016 , 90, 76-91	6.6	151
122	Generation and Characterization of a Bivalent HIV-1 Subtype C gp120 Protein Boost for Proof-of-Concept HIV Vaccine Efficacy Trials in Southern Africa. <i>PLoS ONE</i> , 2016 , 11, e0157391	3.7	25
121	Developmental Pathway of the MPER-Directed HIV-1-Neutralizing Antibody 10E8. <i>PLoS ONE</i> , 2016 , 11, e0157409	3.7	34
120	Immunization with an SIV-based IDLV Expressing HIV-1 Env 1086 Clade C Elicits Durable Humoral and Cellular Responses in Rhesus Macaques. <i>Molecular Therapy</i> , 2016 , 24, 2021-2032	11.7	28
119	Neutralization Takes Precedence Over IgG or IgA Isotype-related Functions in Mucosal HIV-1 Antibody-mediated Protection. <i>EBioMedicine</i> , 2016 , 14, 97-111	8.8	29
118	HIV-1 gp140 epitope recognition is influenced by immunoglobulin DH gene segment sequence. <i>Immunogenetics</i> , 2016 , 68, 145-55	3.2	10

117	Optimization of the Solubility of HIV-1-Neutralizing Antibody 10E8 through Somatic Variation and Structure-Based Design. <i>Journal of Virology</i> , 2016 , 90, 5899-5914	6.6	45
116	A Therapeutic Antibody for Cancer, Derived from Single Human B Cells. <i>Cell Reports</i> , 2016 , 15, 1505-1513	6.6	21
115	Induction of HIV Neutralizing Antibody Lineages in Mice with Diverse Precursor Repertoires. <i>Cell</i> , 2016 , 166, 1471-1484.e18	56.2	132
114	HIV-1 VACCINES. Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies. <i>Science</i> , 2015 , 349, aab1253	33.3	144
113	Stable Expression of Lentiviral Antigens by Quality-Controlled Recombinant Mycobacterium bovis BCG Vectors. <i>Vaccine Journal</i> , 2015 , 22, 726-41		14
112	Broadly Neutralizing Antibodies and the Development of Vaccines. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 313, 2419-20	27.4	13
111	Viral receptor-binding site antibodies with diverse germline origins. <i>Cell</i> , 2015 , 161, 1026-1034	56.2	114
110	CD4 mimetics sensitize HIV-1-infected cells to ADCC. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015 , 112, E2687-94	11.5	89
109	Designing synthetic vaccines for HIV. <i>Expert Review of Vaccines</i> , 2015 , 14, 815-31	5.2	22
108	Eliminating antibody polyreactivity through addition of N-linked glycosylation. <i>Protein Science</i> , 2015 , 24, 1019-30	6.3	8
107	Immune correlates of vaccine protection against HIV-1 acquisition. <i>Science Translational Medicine</i> , 2015 , 7, 310rv7	17.5	142
106	Structural analysis of the unmutated ancestor of the HIV-1 envelope V2 region antibody CH58 isolated from an RV144 vaccine efficacy trial vaccinee. <i>EBioMedicine</i> , 2015 , 2, 713-22	8.8	11
105	Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses. <i>Cell Host and Microbe</i> , 2015 , 18, 354-62	23.4	53
104	Potent immune responses in rhesus macaques induced by nonviral delivery of a self-amplifying RNA vaccine expressing HIV type 1 envelope with a cationic nanoemulsion. <i>Journal of Infectious Diseases</i> , 2015 , 211, 947-55	7	111
103	Infection of monkeys by simian-human immunodeficiency viruses with transmitted/founder clade C HIV-1 envelopes. <i>Virology</i> , 2015 , 475, 37-45	3.6	21
102	Polyreactivity and autoreactivity among HIV-1 antibodies. <i>Journal of Virology</i> , 2015 , 89, 784-98	6.6	123
101	Immunogenic Stimulus for Germline Precursors of Antibodies that Engage the Influenza Hemagglutinin Receptor-Binding Site. <i>Cell Reports</i> , 2015 , 13, 2842-50	10.6	43
100	Longitudinal Antigenic Sequences and Sites from Intra-Host Evolution (LASSIE) Identifies Immune-Selected HIV Variants. <i>Viruses</i> , 2015 , 7, 5443-75	6.2	20

99	Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques. <i>PLoS Pathogens</i> , 2015 , 11, e1005042	7.6	111
98	New approaches to HIV vaccine development. <i>Current Opinion in Immunology</i> , 2015 , 35, 39-47	7.8	70
97	Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors. <i>Cell</i> , 2015 , 161, 1280-92	56.2	219
96	Inhibitory Effect of Individual or Combinations of Broadly Neutralizing Antibodies and Antiviral Reagents against Cell-Free and Cell-to-Cell HIV-1 Transmission. <i>Journal of Virology</i> , 2015 , 89, 7813-28	6.6	31
95	Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein Boost. <i>Journal of Virology</i> , 2015 , 89, 6462-80	6.6	35
94	AIDS/HIV. Host controls of HIV neutralizing antibodies. <i>Science</i> , 2014 , 344, 588-9	33.3	58
93	Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo. <i>Journal of Virology</i> , 2014 , 88, 12669-82	6.6	198
92	Immunoglobulin gene insertions and deletions in the affinity maturation of HIV-1 broadly reactive neutralizing antibodies. <i>Cell Host and Microbe</i> , 2014 , 16, 304-13	23.4	99
91	Human responses to influenza vaccination show seroconversion signatures and convergent antibody rearrangements. <i>Cell Host and Microbe</i> , 2014 , 16, 105-14	23.4	192
90	Vaccine-induced HIV-1 envelope gp120 constant region 1-specific antibodies expose a CD4-inducible epitope and block the interaction of HIV-1 gp140 with galactosylceramide. <i>Journal of Virology</i> , 2014 , 88, 9406-17	6.6	14
89	CD4-mimetic small molecules sensitize human immunodeficiency virus to vaccine-elicited antibodies. <i>Journal of Virology</i> , 2014 , 88, 6542-55	6.6	40
88	HIV-1 envelope gp41 antibodies can originate from terminal ileum B cells that share cross-reactivity with commensal bacteria. <i>Cell Host and Microbe</i> , 2014 , 16, 215-226	23.4	81
87	Cooperation of B cell lineages in induction of HIV-1-broadly neutralizing antibodies. <i>Cell</i> , 2014 , 158, 481-91	36.2	213
86	Structure and immune recognition of trimeric pre-fusion HIV-1 Env. <i>Nature</i> , 2014 , 514, 455-61	50.4	576
85	Lessons from babies: inducing HIV-1 broadly neutralizing antibodies. <i>Nature Medicine</i> , 2014 , 20, 583-5	50.5	5
84	Redemption of autoreactive B cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, 9022-3	11.5	10
83	The Center for HIV/AIDS Vaccine Immunology (CHAVI) multi-site quality assurance program for cryopreserved human peripheral blood mononuclear cells. <i>Journal of Immunological Methods</i> , 2014 , 409, 21-30	2.5	17
82	Improving Mycobacterium bovis bacillus Calmette-Guérin as a vaccine delivery vector for viral antigens by incorporation of glycolipid activators of NKT cells. <i>PLoS ONE</i> , 2014 , 9, e108383	3.7	21

81	Immune System Regulation in the Induction of Broadly Neutralizing HIV-1 Antibodies. <i>Vaccines</i> , 2014 , 2, 1-14	5.3	20
80	Progress in HIV-1 vaccine development. <i>Journal of Allergy and Clinical Immunology</i> , 2014 , 134, 3-10; quiz 11	11.5	49
79	Aggregate complexes of HIV-1 induced by multimeric antibodies. <i>Retrovirology</i> , 2014 , 11, 78	3.6	22
78	Preexisting compensatory amino acids compromise fitness costs of a HIV-1 T cell escape mutation. <i>Retrovirology</i> , 2014 , 11, 101	3.6	11
77	Recombinant Mycobacterium bovis bacillus Calmette-Guérin vectors prime for strong cellular responses to simian immunodeficiency virus gag in rhesus macaques. <i>Vaccine Journal</i> , 2014 , 21, 1385-95		10
76	HIV-1 envelope gp41 broadly neutralizing antibodies: hurdles for vaccine development. <i>PLoS Pathogens</i> , 2014 , 10, e1004073	7.6	23
75	Reconstructing a B-Cell Clonal Lineage. II. Mutation, Selection, and Affinity Maturation. <i>Frontiers in Immunology</i> , 2014 , 5, 170	8.4	77
74	Affinity maturation in an HIV broadly neutralizing B-cell lineage through reorientation of variable domains. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, 10275-80	11.5	63
73	HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities. <i>Journal of Virology</i> , 2014 , 88, 7715-26	6.6	140
72	Antibody light-chain-restricted recognition of the site of immune pressure in the RV144 HIV-1 vaccine trial is phylogenetically conserved. <i>Immunity</i> , 2014 , 41, 909-18	32.3	50
71	Induction of Antibodies with Long Variable Heavy Third Complementarity Determining Regions by Repetitive Boosting with AIDSVAX B/E in RV144 Vaccinees. <i>AIDS Research and Human Retroviruses</i> , 2014 , 30, A36-A36	1.6	1
70	IGHV1-69 B cell chronic lymphocytic leukemia antibodies cross-react with HIV-1 and hepatitis C virus antigens as well as intestinal commensal bacteria. <i>PLoS ONE</i> , 2014 , 9, e90725	3.7	28
69	Low Multiplicity of HIV-1 Infection and No Vaccine Enhancement in VAX003 Injection Drug Users. <i>Open Forum Infectious Diseases</i> , 2014 , 1, ofu056	1	12
68	Gene deletions in Mycobacterium bovis BCG stimulate increased CD8+ T cell responses. <i>Infection and Immunity</i> , 2014 , 82, 5317-26	3.7	12
67	Cross-reactive potential of human T-lymphocyte responses in HIV-1 infection. <i>Vaccine</i> , 2014 , 32, 3995-4000	4.0	4
66	Chemical synthesis of highly congested gp120 V1V2 N-glycopeptide antigens for potential HIV-1-directed vaccines. <i>Journal of the American Chemical Society</i> , 2013 , 135, 13113-20	16.4	54
65	Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies. <i>Immunity</i> , 2013 , 39, 245-58	32.3	254
64	HIV-1 neutralizing antibodies: understanding nature's pathways. <i>Immunological Reviews</i> , 2013 , 254, 225-44	44.3	368

63	Common tolerance mechanisms, but distinct cross-reactivities associated with gp41 and lipids, limit production of HIV-1 broad neutralizing antibodies 2F5 and 4E10. <i>Journal of Immunology</i> , 2013 , 191, 1260-75	5.3	62
62	Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. <i>Nature</i> , 2013 , 496, 469-76	50.4	759
61	Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. <i>Immunity</i> , 2013 , 38, 176-86	32.3	319
60	Progress in HIV-1 vaccine development. <i>Current Opinion in HIV and AIDS</i> , 2013 , 8, 326-32	4.2	42
59	Recognition of synthetic glycopeptides by HIV-1 broadly neutralizing antibodies and their unmutated ancestors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013 , 110, 18214-9	11.5	65
58	B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. <i>Nature Biotechnology</i> , 2012 , 30, 423-33	44.5	351
57	Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design. <i>Journal of Virology</i> , 2012 , 86, 4688-92	6.6	132
56	Immune-correlates analysis of an HIV-1 vaccine efficacy trial. <i>New England Journal of Medicine</i> , 2012 , 366, 1275-86	59.2	1400
55	Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. <i>Journal of Virology</i> , 2011 , 85, 9998-10009	6.6	342
54	Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated. <i>Journal of Experimental Medicine</i> , 2011 , 208, 2237-49	16.6	166
53	B cell responses to HIV-1 infection and vaccination: pathways to preventing infection. <i>Trends in Molecular Medicine</i> , 2011 , 17, 108-16	11.5	35
52	Isolation of a monoclonal antibody that targets the alpha-2 helix of gp120 and represents the initial autologous neutralizing-antibody response in an HIV-1 subtype C-infected individual. <i>Journal of Virology</i> , 2011 , 85, 7719-29	6.6	50
51	Isolation of a human anti-HIV gp41 membrane proximal region neutralizing antibody by antigen-specific single B cell sorting. <i>PLoS ONE</i> , 2011 , 6, e23532	3.7	123
50	HIV-1 autoreactive antibodies: are they good or bad for HIV-1 prevention?. <i>Nature Structural and Molecular Biology</i> , 2010 , 17, 543-5	17.6	14
49	Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic tolerance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010 , 107, 181-6	11.5	144
48	Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies. <i>PLoS Computational Biology</i> , 2010 , 6, e1000955	5	71
47	Is developing an HIV-1 vaccine possible?. <i>Current Opinion in HIV and AIDS</i> , 2010 , 5, 362-7	4.2	24
46	High-throughput isolation of immunoglobulin genes from single human B cells and expression as monoclonal antibodies. <i>Journal of Virological Methods</i> , 2009 , 158, 171-9	2.6	181

45	Glycosylation site-specific analysis of clade C HIV-1 envelope proteins. <i>Journal of Proteome Research</i> , 2009 , 8, 4231-42	5.6	82
44	Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. <i>Journal of Experimental Medicine</i> , 2009 , 206, 1273-89	16.6	600
43	Critical issues in mucosal immunity for HIV-1 vaccine development. <i>Journal of Allergy and Clinical Immunology</i> , 2008 , 122, 3-9; quiz 10-1	11.5	56
42	Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. <i>Journal of Virology</i> , 2008 , 82, 12449-63	6.6	452
41	HIV-1 hides an Achilles heel in virion lipids. <i>Immunity</i> , 2008 , 28, 10-2	32.3	21
40	Glycosylation site-specific analysis of HIV envelope proteins (JR-FL and CON-S) reveals major differences in glycosylation site occupancy, glycoform profiles, and antigenic epitopes accessibility. <i>Journal of Proteome Research</i> , 2008 , 7, 1660-74	5.6	123
39	Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 7552-7	11.5	1472
38	Comparison of HPLC/ESI-FTICR MS versus MALDI-TOF/TOF MS for glycopeptide analysis of a highly glycosylated HIV envelope glycoprotein. <i>Journal of the American Society for Mass Spectrometry</i> , 2008 , 19, 1209-20	3.5	63
37	High throughput functional analysis of HIV-1 env genes without cloning. <i>Journal of Virological Methods</i> , 2007 , 143, 104-11	2.6	44
36	Analysis of HIV-1 subtype B third variable region peptide motifs for induction of neutralizing antibodies against HIV-1 primary isolates. <i>Virology</i> , 2006 , 345, 44-55	3.6	37
35	Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates. <i>Expert Review of Vaccines</i> , 2006 , 5, 579-95	5.2	81
34	Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates. <i>Expert Review of Vaccines</i> , 2006 , 5, 347-63	5.2	69
33	Antibody polyspecificity and neutralization of HIV-1: A hypothesis. <i>Human Antibodies</i> , 2006 , 14, 59-67	1.3	120
32	Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. <i>Science</i> , 2005 , 308, 1906-8	33.3	612
31	Antibody polyspecificity and neutralization of HIV-1: a hypothesis. <i>Human Antibodies</i> , 2005 , 14, 59-67	1.3	103
30	Thymopoiesis in HIV-infected adults after highly active antiretroviral therapy. <i>AIDS Research and Human Retroviruses</i> , 2001 , 17, 1635-43	1.6	41
29	The human thymus during aging. <i>Immunologic Research</i> , 2000 , 22, 253-61	4.3	108
28	HIV vaccine development at Duke University Medical Center. <i>Immunologic Research</i> , 2000 , 22, 263-9	4.3	

27	Cytokines and adhesion molecules in the pathogenesis of vasculitis. <i>Current Rheumatology Reports</i> , 2000 , 2, 402-10	4.9	34
26	The role of the thymus in immune reconstitution in aging, bone marrow transplantation, and HIV-1 infection. <i>Annual Review of Immunology</i> , 2000 , 18, 529-60	34.7	397
25	Changes in thymic function with age and during the treatment of HIV infection. <i>Nature</i> , 1998 , 396, 690-550.4	50.4	1587
24	The human thymus. A chimeric organ comprised of central and peripheral lymphoid components. <i>Immunologic Research</i> , 1998 , 18, 61-78	4.3	38
23	The human thymus. A chimeric organ comprised of central and peripheral lymphoid components. <i>Immunologic Research</i> , 1998 , 18, 175-92	4.3	58
22	Normalization of the peripheral blood T cell receptor V beta repertoire after cultured postnatal human thymic transplantation in DiGeorge syndrome. <i>Journal of Clinical Immunology</i> , 1997 , 17, 167-75	5.7	24
21	Conformational preferences of a chimeric peptide HIV-1 immunogen from the C4-V3 domains of gp120 envelope protein of HIV-1 CAN0A based on solution NMR: comparison to a related immunogenic peptide from HIV-1 RF. <i>Biochemistry</i> , 1996 , 35, 5158-65	3.2	32
20	The mouse CD7 gene: identification of a new element common to the human CD7 and mouse Thy-1 promoters. <i>Immunogenetics</i> , 1996 , 44, 108-114	3.2	1
19	The mouseCD7 gene: Identification of a new element common to the humanCD7 and mouseThy-1 promoters. <i>Immunogenetics</i> , 1996 , 44, 108-114	3.2	5
18	Response : HIV Viral Load Assay. <i>Science</i> , 1996 , 271, 1043-1043	33.3	1
17	Response : HIV Quasispecies and Resampling. <i>Science</i> , 1996 , 273, 416-416	33.3	
16	Response : HIV Viral Load Assay. <i>Science</i> , 1996 , 271, 1043-1043	33.3	
15	Distribution of CD44 variant isoforms in human skin: differential expression in components of benign and malignant epithelia. <i>Journal of Cutaneous Pathology</i> , 1995 , 22, 536-45	1.7	16
14	Increase in TCR gamma delta T lymphocytes in synovia from rheumatoid arthritis patients with active synovitis. <i>Journal of Clinical Immunology</i> , 1992 , 12, 130-8	5.7	31
13	In vivo models of human lymphopoiesis and autoimmunity in severe combined immune deficient mice. <i>Journal of Clinical Immunology</i> , 1992 , 12, 311-24	5.7	17
12	Measurement of an adhesion molecule as an indicator of inflammatory disease activity. Up-regulation of the receptor for hyaluronate (CD44) in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1991 , 34, 1434-43		142
11	Immunohistologic analysis of the distribution of cell adhesion molecules within the inflammatory synovial microenvironment. <i>Arthritis and Rheumatism</i> , 1989 , 32, 22-30		180
10	Synovial microenvironment-T cell interactions. Human T cells bind to fibroblast-like synovial cells in vitro. <i>Arthritis and Rheumatism</i> , 1988 , 31, 947-55		55

9	Ontogeny of the human thymus during fetal development. <i>Journal of Clinical Immunology</i> , 1987 , 7, 81-97	5.7	119
8	Human erythrocyte antigens. III. Characterization of a panel of murine monoclonal antibodies that react with human erythrocyte and erythroid precursor membranes. <i>Vox Sanguinis</i> , 1987 , 52, 236-43	3.1	37
7	Rheumatoid arthritis and sterile corneal ulceration. Analysis of tissue immune effector cells and ocular epithelial antigens using monoclonal antibodies. <i>Arthritis and Rheumatism</i> , 1984 , 27, 606-14		17
6	Leukemia-associated arthritis: identification of leukemic cells in synovial fluid using monoclonal and polyclonal antibodies. <i>Arthritis and Rheumatism</i> , 1984 , 27, 1306-8		30
5	Analysis of Fc gamma receptors on human peripheral blood leukocytes by flow microfluorometry. I. Receptor distributions on monocytes, T gamma cells and cells labeled with the 3A1 anti-T cell monoclonal antibody. <i>European Journal of Immunology</i> , 1982 , 12, 474-9	6.1	21
4	Human T lymphocyte antigens as defined by monoclonal antibodies. <i>Immunological Reviews</i> , 1981 , 57, 127-61	11.3	185
3	Recapitulation of HIV-1 Env-Antibody Coevolution in Macaques Leading to Neutralization Breadth		1
2	Functional Improbable Antibody Mutations Critical for HIV Broadly Neutralizing Antibody Development		1
1	New SHIVs and Improved Design Strategy for Modeling HIV-1 Transmission, Immunopathogenesis, Prevention and Cure		1